Skip to content

News &
Events

news

17
June
2020
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
29
April
2020
RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II Clinical Trial in Urothelial Cancer
15
April
2020
Expanded Access Policy for Investigational product telitacicept
15
April
2020
FDA Grants Fast Track Designation to RemeGen’s Telitacicept as a Treatment for Systemic Lupus Erythematosus
2
April
2020
RemeGen Completes USD $100 Million Plus in Funding
Load more
For media inquiries, please contact Jennifer Gordon at
jgordon@spectrumscience.com